Current antiviral drugs only target one virus: one drug against one virus

OUR BUSINESS IS ANTIVIRALS; OUR APPROACH IS DIFFERENT

The Challenge – Hundreds of viral infections have no cure. Traditional antiviral therapies and vaccines are developed to target one virus at a time; and this limitation is compounded by the fact that few antiviral drugs are able to defend against a virus’s ability to quickly develop drug-resistance.

Broad Spectrum Antivirals – Evrys Bio’s approach to antiviral therapy is different. Uniquely, Evrys Bio antivirals target special human proteins, known as sirtuins, enhancing their natural ability to fight powerful infections. Because the function of sirtuins is essential for different viruses, Evrys Bio antivirals address many, if not all, of the viruses that cause a given infectious disease. For example, our vision is that an Evrys Bio product will address hepatitis caused by hepatitis B virus and hepatitis C virus.  Current products only address one or the other, not both. Furthermore, because sirtuins are the patient’s own proteins, viruses cannot rapidly develop drug-resistance against sirtuin-targeted drugs, completely transforming the way we treat and cure viral infections today.

Management Team

Actualizing Innovation. A proven team advancing today’s innovation into tomorrow’s transformative therapeutics.

Platform & Pipeline

Next Gen Antivirals that engage the patient’s own immunity to naturally defend against viral infection without the emergence of drug resistance.

News

Transformative Achievements. Evrys Bio in the News.

Evrys Bio

Advancing today‘s life science innovation into tomorrow’s transformative therapeutics

Innovation
Evrys Bio was founded on breakthrough discoveries from Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the patient’s cellular intrinsic immunity to fight viral infections. Our vision is to develop safe, first-in-class antivirals that address the problem of acquired drug-resistance and provide unique broad-spectrum treatment options.  Because Evrys Bio products address the infectious disease condition, as opposed to targeting a specific virus-type, the practice of medicine will be transformed. Imagine being prescribed a safe, broad-spectrum antiviral based on your symptoms presentation, and perhaps, without the need for diagnostic confirmation of infecting virus. These highly-innovative products are early-stage, yet we are making great progress in solving real clinical challenges and unmet medical need.

Actualization
Evrys Bio has four drug discovery programs that apply our broad-spectrum antiviral technology to address unique clinical challenges unmet by current antiviral drugs:

  • an antiviral for treating pan-respiratory infections with demonstrated effectiveness against coronaviruses, respiratory syncytial virus, adenoviruses and seasonal, pandemic, influenza A and B strains, including ones resistant to current drugs;
  • a single pill effective for immunosuppressed patients receiving organ transplants that will protect against multiple (opportunistic) infections including herpes family viruses and polyomavirus infections posing serious complications;
  • a biodefense, medical countermeasure for pandemic preparedness against newly emerging viruses; and
  • a broad spectrum antiviral agent targeting the major causes of hepatitis including B, C, D and E viruses.

© Copyright - Evrys Bio